PT - JOURNAL ARTICLE AU - Peluso, Michael J. AU - Deitchman, Amelia N. AU - Torres, Leonel AU - Iyer, Nikita S. AU - Nixon, Christopher C. AU - Munter, Sadie E. AU - Donatelli, Joanna AU - Thanh, Cassandra AU - Takahashi, Saki AU - Hakim, Jill AU - Turcios, Keirstinne AU - Janson, Owen AU - Hoh, Rebecca AU - Tai, Viva AU - Hernandez, Yanel AU - Fehrman, Emily AU - Spinelli, Matthew A. AU - Gandhi, Monica AU - Trinh, Lan AU - Wrin, Terri AU - Petropoulos, Christos J. AU - Aweeka, Francesca T. AU - Rodriguez-Barraquer, Isabel AU - Kelly, J. Daniel AU - Martin, Jeffrey N. AU - Deeks, Steven G. AU - Greenhouse, Bryan AU - Rutishauser, Rachel L. AU - Henrich, Timothy J. TI - Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19 AID - 10.1101/2021.02.26.21252308 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.26.21252308 4099 - http://medrxiv.org/content/early/2021/03/01/2021.02.26.21252308.short 4100 - http://medrxiv.org/content/early/2021/03/01/2021.02.26.21252308.full AB - A detailed understanding of long-term SARS-CoV-2-specific T cell responses and their relationship to humoral immunity and markers of inflammation in diverse groups of individuals representing the spectrum of COVID-19 illness and recovery is urgently needed. Data are also lacking as to whether and how adaptive immune and inflammatory responses differ in individuals that experience persistent symptomatic sequelae months following acute infection compared to those with complete, rapid recovery. We measured SARS-CoV-2-specific T cell responses, soluble markers of inflammation, and antibody levels and neutralization capacity longitudinally up to 9 months following infection in a diverse group of 70 individuals with PCR-confirmed SARS-CoV-2 infection. The participants had varying degrees of initial disease severity and were enrolled in the northern California Long-term Impact of Infection with Novel Coronavirus (LIINC) cohort. Adaptive T cell responses remained remarkably stable in all participants across disease severity during the entire study interval. Whereas the magnitude of the early CD4+ T cell immune response is determined by the severity of initial infection (participants requiring hospitalization or intensive care), pre-existing lung disease was significantly associated with higher long-term SARS-CoV2-specific CD8+ T cell responses, independent of initial disease severity or age. Neutralizing antibody levels were strongly correlated with SARS-CoV-2-specific CD4+ T but not CD8+ T cell responses. Importantly, we did not identify substantial differences in long-term virus-specific T cell or antibody responses between participants with and without COVID-19-related symptoms that persist months after initial infection.Competing Interest StatementLT, TW, and CJP are employees of Monogram Biosciences, Inc., a division of LabCorp. TJH reports grants from Merck and Co., Gilead Biosciences, and Bristol-Myers Squibb outside the submitted work.Clinical TrialNCT04362150Funding StatementThis work was supported by the National Institute of Allergy and Infectious Diseases (NIH/NIAID 3R01AI141003-03S1 [to TJ Henrich], NIH/NIAID R01AI158013 [to M Gandhi and M Spinelli] and by the Zuckerberg San Francisco Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine. This work is also supported by a Merck and Co. Investigator Studies Program grant (to TJ Henrich). MJP is supported on NIH T32 AI60530-12 and by the UCSF Resource Allocation Program. ST is supported by the Schmidt Science Fellow, in partnership with the Rhodes Trust. IRB and ST acknowledge research funding from the MIDAS Coordination Center COVID-19 Urgent Grant Program (MIDASNI2020-5). AND is supported by NIH R01 AI141003, R01 HD068174, and the UCSF Resource Allocation Program. The flow cytometry core is supported by the UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the UCSF Institutional Review Board (IRB# 20-30479). All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data supporting the conclusions of this article will be made available by the authors upon request. All data points are shown as individual values in the graphs.